Ed Kelly, PhD, Assistant Director of the Pharmaceutical Bioengineering Extension Program at the University of Washington School of Pharmacy, and co-researcher Jonathan Himmelfarb, MD, are leading a study…
The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The…
According to the Associated Press’ search of a U.S. government database, six of the eight currently registered clinical trials studying deep brain stimulation (DBS) for addiction treatment are…
Researchers in Australia are developing new approaches to blocking inflammasomes, the multiprotein molecular complex that stimulates the body’s inflammatory immune response and drives the progression of Parkinson’s disease…
